Financial Performance - Revenue for the year ended December 31, 2024, reached RMB 5,538.8 million, a 57.2% increase from RMB 3,524.1 million in 2023[3] - Gross profit for the same period was RMB 4,546.9 million, reflecting a 54.3% growth compared to RMB 2,947.1 million in 2023[3] - Profit before tax increased by 40.8% to RMB 2,457.8 million from RMB 1,745.1 million in the previous year[3] - Net profit for the year was RMB 2,061.7 million, up 42.4% from RMB 1,448.2 million in 2023[3] - Basic earnings per share rose to RMB 2.10, a 40.9% increase from RMB 1.49 in 2023[6] - Adjusted net profit (non-IFRS) for the year was RMB 2,151.5 million, representing a 46.5% increase from RMB 1,468.7 million in 2023[3] - Total comprehensive income for the year amounted to RMB 2,073.5 million, compared to RMB 1,448.2 million in 2023[6] Dividends - The board recommended a final dividend of RMB 0.6021 per ordinary share and a special dividend of RMB 0.5921 per ordinary share[3] - The company proposed a final dividend of RMB 0.6021 per share and a special dividend of RMB 0.5921 per share for 2024, totaling approximately RMB 1,237,037,000, pending shareholder approval[36] - The expected payment date for the proposed dividends is around August 29, 2025[127] Assets and Liabilities - Non-current assets increased to RMB 1,636,001 thousand in 2024 from RMB 837,999 thousand in 2023, representing a growth of 95.4%[7] - Current assets rose to RMB 6,401,957 thousand in 2024, up from RMB 4,135,079 thousand in 2023, marking a 55.0% increase[7] - Total liabilities increased to RMB 918,136 thousand in 2024 from RMB 602,028 thousand in 2023, reflecting a growth of 52.5%[8] - The company's net asset value reached RMB 7,119,822 thousand in 2024, compared to RMB 4,371,050 thousand in 2023, an increase of 62.9%[8] - Cash and cash equivalents surged to RMB 4,030,207 thousand in 2024, up from RMB 2,503,999 thousand in 2023, a growth of 60.9%[7] - Trade payables increased to RMB 286,708 thousand in 2024 from RMB 133,109 thousand in 2023, a rise of 115.5%[7] - The company reported a significant increase in inventory, which rose to RMB 310,814 thousand in 2024 from RMB 200,440 thousand in 2023, a growth of 55.0%[7] Research and Development - Research and development expenses increased to RMB 106.5 million from RMB 74.9 million, indicating a focus on innovation[5] - The company has 188 ongoing research projects and has been granted or applied for 167 patents, with 74 new patents added during the reporting period[55] - The company plans to increase R&D investment and enhance its product offerings, focusing on three categories of medical devices for clinical approval[76] Revenue Sources - Customer contract revenue for the year ended December 31, 2024, reached RMB 5,538,812 thousand, a significant increase of 57.2% compared to RMB 3,524,143 thousand in 2023[27] - All revenue for the group is derived from customers located in mainland China, with no contributions from other regions[25] - Revenue from professional skincare products amounted to RMB 4,302.3 million, representing 77.7% of total revenue, up from RMB 2,647.3 million (75.1%) in the previous year[77] - Direct sales through DTC online stores generated RMB 3,587.2 million, a 66.5% increase from RMB 2,154.5 million (61.2%) in 2023, accounting for 64.8% of total revenue[81] Marketing and Sales - The company achieved top sales rankings in the medical dressing category on major platforms during the 2024 promotional events, including being ranked TOP1 on Tmall and JD for medical dressings[60] - The company launched a "Bottle Recycling Program" to promote ecological responsibility and engage with younger consumers through skincare education initiatives[66] - The company's online channel GMV growth exceeded 60% and 100% during the 2024 618 promotion for its brands, reflecting strong consumer preference[70] Corporate Governance - The company has complied with all applicable provisions of the corporate governance code, except for a deviation regarding the roles of the Chairman and CEO[118] - The company believes that having the same individual serve as both Chairman and CEO provides strong and effective leadership for business strategy execution[118] - All directors confirmed compliance with the standard code for securities trading during the reporting period[119] Future Outlook - The company believes in the significant potential of the beauty and health industry in China, with optimistic future prospects[76] - The company plans to gradually utilize the raised funds over the next three years based on actual business conditions, with the allocation subject to change according to market developments[124]
巨子生物(02367) - 2024 - 年度业绩